Kearny Financial Corp. (KRNY) · Oct 22, 2026 · Earnings
Miss — Diluted EPS $0.16 vs ~$0.17 consensus
Kearny Financial’s earnings miss consensus, though lower expenses, deposit growth and a commercial loan remix strengthen the underlying transition.
Kearny is in the middle of a known repositioning: shifting from a multifamily-heavy thrift toward relationship-based commercial banking, higher-yielding commercial and construction loans, and a broader deposit franchise. That strategy was already established before this release, so the new information is whether execution is translating into earnings power. The quarter missed the published earnings bar. Diluted EPS was $0.16 versus a published consensus of roughly $0.17, while revenue of $45.3 million was below published estimates near $47.0 million.
| Metric | Q1 FY2027 | Q4 FY2026 / prior comparison | Read |
|---|---|---|---|
| Diluted EPS | $0.16 | $0.11 | Below ~$0.17 consensus |
| Net income | $10.0M | $7.2M | +40.0% sequentially |
| Adjusted pre-tax, pre-provision revenue | $13.5M | $12.6M adjusted | +7.3% sequentially |
| Net interest margin | 2.23% | 2.26% | Down 3 bps |
| Loans | $5.98B | $5.88B | +1.8% sequentially |
| Deposits | $5.83B | $5.71B | +2.2% sequentially |
| Non-interest expense | $31.8M | $33.9M | Down 6.1% |
| Tangible equity / tangible assets | 8.37% | 8.62% | Down 25 bps |
The headline miss overstates the deterioration. Net income rose to $10.0 million, but the comparison benefited from the prior quarter’s $1.6 million deferred-tax-asset valuation allowance; adjusted EPS was $0.16 versus $0.15 in Q4, so the cleaner signal is modest improvement rather than a step-change. The filing says, “reported net income for the quarter ended September 30, 2026 of $10.0 million, or $0.16 per diluted share.”
Underlying operating leverage did improve. Pre-tax, pre-provision revenue rose to $13.5 million, while non-interest expense fell 6.1% to $31.8 million; however, much of the expense decline came from lapping prior-period severance and lower discretionary costs rather than a broad structural reset. The filing says, “For the quarter ended September 30, 2026, non-interest expense decreased $2.1 million, or 6.1%, to $31.8 million.”
The balance-sheet repositioning is progressing, but margin conversion remains incomplete. Loans grew 1.8% sequentially as commercial and construction balances expanded while multifamily declined, and deposits grew 2.2%; yet net interest margin slipped to 2.23% because higher asset yields were offset by more expensive wholesale funding and lower prepayment-related income. Excluding purchase-accounting accretion and prepayment penalties, net interest income increased $132,000, which supports the company’s claim that core earnings are improving, but the reported margin still moved backward. The filing says, “Excluding loan prepayment penalty income and purchase accounting accretion, net interest income increased $132,000 from the prior period.”
Credit stayed controlled, while capital absorbed another mark-to-market hit. Net charge-offs remained very low at 0.02% of average loans and the allowance stayed at 0.77% of loans, but tangible book value per share fell to $9.88 as unrealized securities losses widened; tangible capitalization remained solid at 8.37%, limiting the immediate concern but reducing balance-sheet flexibility at the margin.
Bottom line: This was a modest earnings miss, not a breakdown in the repositioning story. The core transition is moving forward through loan remix, deposit growth and lower costs, but the quarter did not yet prove that those gains can consistently overcome funding pressure and produce above-expectation earnings.՝
2027 multifamily and CRE loan repricing cycle
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!